Search Results for "Weight Loss"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Weight Loss. Results 201 to 210 of 215 total matches.
Drugs for Menopausal Symptoms
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024 (Issue 1697)
thromboembolic and other systemic adverse
effects11,12; they are generally preferred for women
with obesity ...
The primary symptoms of menopause are genitourinary
and vasomotor. The genitourinary syndrome
of menopause (GSM) includes symptoms such as
burning, irritation, dryness, dyspareunia, dysuria,
and recurrent urinary tract infection. Vasomotor
symptoms (VMS; hot flashes, night sweats) often
disrupt sleep.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):33-8 doi:10.58347/tml.2024.1697a | Show Introduction Hide Introduction
Antiviral Drugs for Seasonal Influenza for 2024-2025
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024 (Issue 1717)
with
aspirin or salicylate-containing drugs
▶ Adults ≥65 years old
▶ Persons with obesity (BMI ≥40 kg/m2 ...
Influenza is generally a self-limited illness, but
pneumonia, respiratory failure, and death can occur,
especially in persons at increased risk for influenza
complications (see Table 1). Updated information on
influenza activity and antiviral resistance is available
from the CDC at cdc.gov/flu.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):193-8 doi:10.58347/tml.2024.1717a | Show Introduction Hide Introduction
Drugs for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Mar 22, 2021 (Issue 1620)
, and
obesity, but not disease-modifying therapy exposure,
were associated with increased COVID-19 severity.45 ...
Most patients with multiple sclerosis (MS) present
with the relapsing-remitting form of the disease.
Pharmacologic treatment usually includes a
disease-modifying drug, corticosteroids for acute
exacerbations, and other drugs for managing
symptoms such as fatigue, depression, and pain.
Early use of disease-modifying therapy has improved
clinical outcomes.
Drugs for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
, and hepatotoxicity have been
reported. Anaphylaxis, Stevens-Johnson syndrome,
weight loss, interstitial lung ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of
adults in the US; it is about 2.5 times more common
in women than in men. Guidelines for treatment
of RA from the American College of Rheumatology
were recently updated. The goal of treatment is to
minimize disease activity and prevent irreversible
joint damage.
Drugs for Cognitive Loss and Dementia
The Medical Letter on Drugs and Therapeutics • Aug 22, 2022 (Issue 1657)
, headache, and weight loss are common
with rapid dose escalation of galantamine, but
The Medical Letter ...
Alzheimer's disease (AD) is the most common
cause of dementia, but cognitive decline is also
associated with other neurological conditions such
as Parkinson's disease, dementia with Lewy bodies,
vascular dementia, and frontotemporal dementia.
Antifungal Drugs
Treatment Guidelines from The Medical Letter • Aug 01, 2012 (Issue 120)
. Weight loss,
malaise, anemia, thrombocytopenia and mild
leukopenia can occur. Cardiac toxicity ...
The drugs of choice for treatment of fungal infections
are listed in the table that begins on page 62. Some of
the indications and dosages recommended here have
not been approved by the FDA. More detailed guidelines
for some of these infections are available online
from the Infectious Diseases Society of America
(www.idsociety.org).
Drugs for Psoriatic Arthritis
The Medical Letter on Drugs and Therapeutics • Dec 30, 2019 (Issue 1588)
-Johnson syndrome, weight
loss, interstitial lung disease, peripheral neuropathy,
and leukocytoclastic ...
Psoriatic arthritis is a chronic inflammatory
arthropathy associated with psoriasis. A recent review
found that about 20% of patients with psoriasis have
psoriatic arthritis. Updated guidelines for treatment
of psoriatic arthritis have recently been published.
Drugs for Anxiety Disorders
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
for treatment of anxiety, particularly in
patients with insomnia or weight loss, but evidence
from clinical ...
Anxiety disorders (generalized anxiety disorder,
panic disorder, social anxiety disorder, and various
phobias) are the most common form of psychiatric
illness. They can be treated effectively with cognitive
behavioral therapy (CBT) and/or pharmacotherapy.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):121-8 doi:10.58347/tml.2023.1682a | Show Introduction Hide Introduction
Drugs for COPD
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024 (Issue 1710)
of
roflumilast include nausea and diarrhea. Significant
weight loss and changes in mood and behavior ...
The main goals of treatment of chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
prevent disease progression, and reduce mortality.
GOLD (Global Initiative for Chronic Obstructive Lung
Disease) guidelines for treatment of COPD were
updated recently. Treatment of acute exacerbations
is not discussed here. Drugs available for treatment
of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44 doi:10.58347/tml.2024.1710a | Show Introduction Hide Introduction
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
,
language and cognitive impairment, taste perversion,
weight loss, and nephrolithiasis can also occur ...
An oral nonopioid analgesic is often sufficient for
acute treatment of mild to moderate migraine pain
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to severe
migraine in most patients without vascular disease.
Treatment of pain when it is still mild to moderate in
intensity improves headache response and reduces
the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96 doi:10.58347/tml.2023.1678a | Show Introduction Hide Introduction